Wiegand RA - Search Results

1

Cryptophycin 1 cellular levels and effects in vitro using L1210 cells.

Foster BJ, Fortuna M, Media J, Wiegand RA, Valeriote FA. Foster BJ, et al. Among authors: wiegand ra. Invest New Drugs. 1998-1999;16(3):199-204. doi: 10.1023/a:1006148127527. Invest New Drugs. 1998. PMID: 10360599

2

Inhibition of macromolecular synthesis by cryptophycin-52.

Subramanian B, Nakeff A, Media JE, Wiegand RA, Valeriote FA. Subramanian B, et al. Among authors: wiegand ra. Anticancer Drugs. 2002 Nov;13(10):1061-8. doi: 10.1097/00001813-200211000-00010. Anticancer Drugs. 2002. PMID: 12439340

3

Preclinical anticancer activity of cryptophycin-8.

Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, White K, Knight J, Jones J, Jones L, LoRusso P, Foster B, Wiegand RA, Lisow L, Golakoti T, Heltzel CE, Ogino J, Patterson GM, Moore RE. Corbett TH, et al. Among authors: wiegand ra. J Exp Ther Oncol. 1996 Mar;1(2):95-108. J Exp Ther Oncol. 1996. PMID: 9414393

4

Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline).

Foster BJ, Jones L, Wiegand R, LoRusso PM, Corbett TH. Foster BJ, et al. Invest New Drugs. 1997;15(3):187-94. doi: 10.1023/a:1005846026398. Invest New Drugs. 1997. PMID: 9387041

5

Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.

Foster BJ, Wiegand RA, LoRusso PM, Baker LH. Foster BJ, et al. Among authors: wiegand ra. Clin Cancer Res. 1995 Aug;1(8):831-7. Clin Cancer Res. 1995. PMID: 9816052

6

Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC-366140).

Palomino E, Foster B, Kempff M, Corbett T, Wiegand R, Horwitz J, Baker L. Palomino E, et al. Cancer Chemother Pharmacol. 1996;38(5):453-8. doi: 10.1007/s002800050510. Cancer Chemother Pharmacol. 1996. PMID: 8765439

7

Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.

Foster BJ, Wiegand RA, Pugh S, LoRusso PM, Rake J, Corbett TH. Foster BJ, et al. Among authors: wiegand ra. Clin Cancer Res. 1997 Nov;3(11):2047-53. Clin Cancer Res. 1997. PMID: 9815596

8

A liquid chromatography with tandem mass spectrometry method for simultaneous determination of UTL-5g and its metabolites in human plasma.

Shaw J, Wiegand R, Wu J, Bao X, Valeriote F, Li J. Shaw J, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jun 1;991:92-8. doi: 10.1016/j.jchromb.2015.04.015. Epub 2015 Apr 18. J Chromatogr B Analyt Technol Biomed Life Sci. 2015. PMID: 25955381 Free PMC article.

9

A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design.

Gadgeel SM, Boinpally RR, Heilbrun LK, Wozniak A, Jain V, Redman B, Zalupski M, Wiegand R, Parchment R, LoRusso PM. Gadgeel SM, et al. Invest New Drugs. 2003 Feb;21(1):63-74. doi: 10.1023/a:1022972427532. Invest New Drugs. 2003. PMID: 12795531 Free article. Clinical Trial.

10

Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.

Boinpally RR, Polin L, Zhou SL, Jasti BR, Wiegand RA, White K, Kushner J, Horwitz JP, Corbett TH, Parchment RE. Boinpally RR, et al. Among authors: wiegand ra. Cancer Chemother Pharmacol. 2003 Jul;52(1):25-33. doi: 10.1007/s00280-003-0621-0. Epub 2003 May 9. Cancer Chemother Pharmacol. 2003. PMID: 12739061

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters